TScan Therapeutics, Inc. (TCRX): R&D Expense
$114.15M
Year ended 2025-12-31
$97.03M
Trailing 12 months to 2026-06-30
+24.0%
3-year compound annual growth
+40.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $114.15M | +6.3% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $107.35M | +21.8% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $88.15M | +47.4% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $59.82M | +33.1% | 2024-03-06, From 2022-01-01 |
| 2021-12-31 | $44.95M | +118.5% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $20.58M | n/a | 2022-03-09, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $86.40M | +30.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| Curis Inc (CRIS) | 2025-12-31 | $28.25M | -26.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $261.38M | -18.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
Compare TCRX, ACOG, TSHA, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗